The deactivation of NF-κB by an IRAK1/4 inhibitor with imatinib was extremely effective at eliminating CML LSCs compared with imatinib alone in a mouse CML-like model and a xenograft model with primary CML-CP patient samples. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.